famotidine has been researched along with Recrudescence in 45 studies
Famotidine: A competitive histamine H2-receptor antagonist. Its main pharmacodynamic effect is the inhibition of gastric secretion.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Frequent heartburn sufferers (n = 366) were randomized to receive double blind treatment with famotidine 10 mg or 2 x 250 mg chewable alginate tablets within 30 min of a spontaneous episode of heartburn." | 9.08 | Prevention of heartburn relapse by low-dose famotidine: a test meal model for duration of symptom control. ( Cottrell, J; Mann, SG; Murakami, A; Rao, AN; Stauffer, L, 1997) |
| "Fifty-three consecutive patients with active duodenal ulcer (DU) were randomly included in a double-blind, double-dummy study to test the healing and relapsing rate of two treatment regimens: famotidine 40 mg nocte for 4-8 weeks, followed by 20 mg for 12 months after healing of the ulcer and colloidal bismuth (CBS) (240 mg bid) for 4-8 weeks, followed by placebo maintenance treatment." | 9.08 | Colloid bismuth versus famotidine in the treatment and prevention of duodenal ulcer relapse: results of a double-blind, double dummy randomized study. ( Colombo, E; Fanti, L; Guslandi, M; Masci, E; Testoni, PA; Tittobello, A, 1995) |
| "5 mg twice daily), amantadine (100 mg nocte), or with the H2 blockers cimetidine (800 mg nocte), and famotidine (40 mg nocte) in 124 patients with endoscopically proven duodenal ulcer (DU)." | 9.07 | Dopamine agonists prevent duodenal ulcer relapse. A comparative study with famotidine and cimetidine. ( Duvnjak, M; Jagic, V; Mise, S; Petek, M; Rotkvic, I; Rucman, R; Seiwerth, S; Sikiric, P; Suchanek, E; Zjacic-Rotkvic, V, 1991) |
| "Forty-four patients with esophagitis refractory to standard H2-blocker therapy, who had healed after a 4- to 16-wk course with either 20-40 mg omeprazole or ranitidine at doses of 300-600 mg daily in a randomized double-blind study, commenced a 3-month maintenance course of therapy with 40 mg bid famotidine." | 9.07 | High-dose famotidine in the maintenance treatment of refractory esophagitis: results of a "medium-term" open study. ( Bianchi-Porro, G; Bonavina, L; Pace, F; Peracchia, A; Sangaletti, O; Termini, R; Vigneri, S, 1991) |
| "A multicentre, double-blind, randomized, placebo-controlled trial was undertaken to investigate the therapeutic efficacy of a nocturnal dose of famotidine 20 mg to reduce the 1 year relapse rate of recently healed gastric ulcers." | 9.07 | Nocturnal therapy with famotidine for 1 year is effective in preventing relapse of gastric ulcer. ( Berlin, RG; Cook, TJ; Root, JK, 1991) |
| "Sixty patients with symptomatic duodenal ulcer were randomized to receive either omeprazole (20 mg each morning) or famotidine (40 mg at night time) for 2-4 weeks in a double-blind parallel group clinical trial." | 9.07 | Omeprazole versus famotidine in the healing and relapse of duodenal ulcer. ( Dasarathy, S; Misra, SC; Sharma, MP, 1993) |
| " In this 2:1 randomized, double-blind, multicentre trial lansoprazole 30 mg am was compared to 40 mg famotidine nocte in 264 out-patients suffering from uncomplicated duodenal ulcer." | 9.07 | Lansoprazole versus famotidine: efficacy and tolerance in the acute management of duodenal ulceration. ( Grymbowski, T; Hennig, U; Hotz, J; Kleinert, R; Schwarz, JA, 1992) |
| "The aim of this study was to gain experience concerning efficacy and safety of famotidine, the new H2-receptor antagonist, for the maintenance of duodenal ulcer disease." | 9.05 | [Famotidine versus placebo in prevention of the recurrence of duodenal ulcer disease. A multicenter study in Germany, Austria and Italy]. ( Baglioni, A; Barbara, L; Bianchi-Porro, G; Blasi, A; Canelli, B; Cheli, R; Dal Monte, R; Dammann, HG; Francavilla, A; Hentschel, E, 1985) |
| "Effect of lafutidine ((+/-)-2-(furfurylsulfinyl)-N-[4-[4-(piperidinomethyl)-2-pyr idyl] oxy-(Z)-2-butenyl] acetamide, FRG-8813), a novel antiulcer agent, on the healing and relapse in acetic acid-induced gastric ulcer in rats was investigated." | 7.70 | [Effect of lafutidine, a novel antiulcer agent, on healing and relapse of acetic acid-induced gastric ulcer in rats]. ( Aoyama, M; Arai, Y; Ohnishi, H; Onodera, S; Shibata, M; Tanaka, M; Yamaura, T, 1998) |
| "We retrospectively investigated the efficacy of high dose omeprazole compared to a combined therapy of famotidine, pirenzepine and antacid for acute upper gastrointestinal hemorrhage (AUGIH) also adjuvant to endoscopic injection therapy if indicated." | 7.69 | [High-dose omeprazole versus famotidine, pirenzepine and antacid in therapy of acute upper gastrointestinal hemorrhage in a retrospective comparison]. ( Busam, J; Garbe, WE, 1994) |
| "In this open trial, 25 patients with identified duodenal ulcers were given long-term therapy of a single evening dose of 20 mg famotidine." | 7.68 | [Prevention of the recurrence of duodenal ulcer with famotidine. Report of experiences with long-term therapy in an open clinical study]. ( Judmaier, G, 1992) |
| "for the prevention of duodenal ulcer recurrence." | 6.67 | A controlled study of 20 mg famotidine nocte vs. 150 mg ranitidine nocte for the prevention of duodenal ulcer relapse. ( Barbara, L; Bianchi Porro, G; Blasi, A; Bovero, E; Capurso, L; Cheli, R; Corinaldesi, R; Koch, M; Lazzaroni, M; Mangiameli, A, 1991) |
| " Recurrent upper GI bleeding occurred in one patient receiving lansoprazole (duodenal ulcer) and three receiving famotidine (two gastric ulcers and one duodenal ulcer)." | 5.34 | Prevention of recurrent idiopathic gastroduodenal ulcer bleeding: a double-blind, randomised trial. ( Chan, FKL; Ching, JYL; Chiu, PWY; Lau, JYW; Lau, LHS; Ling, RHY; Tse, YK; Wong, GLH; Wong, VWS, 2020) |
| "Operative management also reduces recurrence rates, which, however, are commoner in patients coming to surgery nowadays." | 5.28 | High doses of ranitidine in maintenance therapy of duodenal ulcer patients. ( Lee, FI, 1990) |
| "From January 2012 to 2016, long-termed thienopyridine users with a peptic ulcer history who did not have peptic ulcers at initial endoscopy were randomly assigned to receive either famotidine (40 mg, before bedtime) or placebo (before bedtime) for 6 months." | 5.24 | Histamine-2 Receptor Antagonist Cannot Prevent Recurrent Peptic Ulcers in Patients With Atherosclerotic Diseases Who Receive Platelet ADP Receptor Antagonist Monotherapy: A Randomized-Controlled, Double-Blind, and Double-Dummy Trial. ( Chen, WC; Cheng, JS; Hsu, PI; Kao, SS; Lai, KH; Liu, CP; Tsai, KW; Tsai, TJ; Tsay, FW; Wang, HM; Wu, DC, 2017) |
| "Heartburn, regurgitation and dysphagia were hardly found in any group at 8 weeks after 15 mg or 30 mg lansoprazole treatment." | 5.11 | Management of symptoms in step-down therapy of gastroesophageal reflux disease. ( Iida, T; Kishikawa, H; Mine, S; Tabata, T; Tanaka, Y, 2005) |
| "Fifty-three consecutive patients with active duodenal ulcer (DU) were randomly included in a double-blind, double-dummy study to test the healing and relapsing rate of two treatment regimens: famotidine 40 mg nocte for 4-8 weeks, followed by 20 mg for 12 months after healing of the ulcer and colloidal bismuth (CBS) (240 mg bid) for 4-8 weeks, followed by placebo maintenance treatment." | 5.08 | Colloid bismuth versus famotidine in the treatment and prevention of duodenal ulcer relapse: results of a double-blind, double dummy randomized study. ( Colombo, E; Fanti, L; Guslandi, M; Masci, E; Testoni, PA; Tittobello, A, 1995) |
| "Frequent heartburn sufferers (n = 366) were randomized to receive double blind treatment with famotidine 10 mg or 2 x 250 mg chewable alginate tablets within 30 min of a spontaneous episode of heartburn." | 5.08 | Prevention of heartburn relapse by low-dose famotidine: a test meal model for duration of symptom control. ( Cottrell, J; Mann, SG; Murakami, A; Rao, AN; Stauffer, L, 1997) |
| "Sixty patients with symptomatic duodenal ulcer were randomized to receive either omeprazole (20 mg each morning) or famotidine (40 mg at night time) for 2-4 weeks in a double-blind parallel group clinical trial." | 5.07 | Omeprazole versus famotidine in the healing and relapse of duodenal ulcer. ( Dasarathy, S; Misra, SC; Sharma, MP, 1993) |
| "The purpose of the work was an evaluation of duodenal ulcer recurrence rate in patients with a history of at least two years of ulcer treated during one year with the preparation Ulfamid (famotidine) Krka in a maintenance dose of 20 mg before sleep." | 5.07 | [Clinical evaluation of one-year controlled studies of duodenal ulcer recurrence rate in patients treated with the preparation Ulfamid]. ( Gabryelewicz, A; Jaroszewicz-Heigelmann, H; Kosidło, S; Marlicz, K, 1993) |
| "In a two center open uncontrolled clinical trial, the efficacy of a single evening dose of 40 mg famotidine (Ulcusan) was studied in a total of 37 patients (20 with chronic duodenal ulcers, 9 with recurring and 8 with acute gastric ulcers)." | 5.07 | [Therapy of peptic ulcers with famotidine. Report of experiences with an open clinical study]. ( Dragosics, B; Okulski, G; Weiss, W, 1992) |
| " In this 2:1 randomized, double-blind, multicentre trial lansoprazole 30 mg am was compared to 40 mg famotidine nocte in 264 out-patients suffering from uncomplicated duodenal ulcer." | 5.07 | Lansoprazole versus famotidine: efficacy and tolerance in the acute management of duodenal ulceration. ( Grymbowski, T; Hennig, U; Hotz, J; Kleinert, R; Schwarz, JA, 1992) |
| "A multicentre, double-blind, randomized, placebo-controlled trial was undertaken to investigate the therapeutic efficacy of a nocturnal dose of famotidine 20 mg to reduce the 1 year relapse rate of recently healed gastric ulcers." | 5.07 | Nocturnal therapy with famotidine for 1 year is effective in preventing relapse of gastric ulcer. ( Berlin, RG; Cook, TJ; Root, JK, 1991) |
| "Forty-four patients with esophagitis refractory to standard H2-blocker therapy, who had healed after a 4- to 16-wk course with either 20-40 mg omeprazole or ranitidine at doses of 300-600 mg daily in a randomized double-blind study, commenced a 3-month maintenance course of therapy with 40 mg bid famotidine." | 5.07 | High-dose famotidine in the maintenance treatment of refractory esophagitis: results of a "medium-term" open study. ( Bianchi-Porro, G; Bonavina, L; Pace, F; Peracchia, A; Sangaletti, O; Termini, R; Vigneri, S, 1991) |
| "5 mg twice daily), amantadine (100 mg nocte), or with the H2 blockers cimetidine (800 mg nocte), and famotidine (40 mg nocte) in 124 patients with endoscopically proven duodenal ulcer (DU)." | 5.07 | Dopamine agonists prevent duodenal ulcer relapse. A comparative study with famotidine and cimetidine. ( Duvnjak, M; Jagic, V; Mise, S; Petek, M; Rotkvic, I; Rucman, R; Seiwerth, S; Sikiric, P; Suchanek, E; Zjacic-Rotkvic, V, 1991) |
| "The aim of this study was to gain experience concerning efficacy and safety of famotidine, the new H2-receptor antagonist, for the maintenance of duodenal ulcer disease." | 5.05 | [Famotidine versus placebo in prevention of the recurrence of duodenal ulcer disease. A multicenter study in Germany, Austria and Italy]. ( Baglioni, A; Barbara, L; Bianchi-Porro, G; Blasi, A; Canelli, B; Cheli, R; Dal Monte, R; Dammann, HG; Francavilla, A; Hentschel, E, 1985) |
| " pylori-infected patients with duodenal ulcer were treated with either omeprazole or famotidine plus two antibiotics for 2 wk." | 3.70 | The long-term reinfection rate and the course of duodenal ulcer disease after eradication of Helicobacter pylori in a developing country. ( Acevedo, C; Duarte, I; Figueroa, C; Fuster, F; Giancaspero, R; Hola, K; Rollan, A; Schulz, M, 2000) |
| "We investigated the influence of T-593, a novel anti-ulcer agent, on the recurrence and relapse of cryocautery-induced gastric ulcer in rats, in comparison with the action of famotidine and ranitidine." | 3.70 | [Influence of T-593 on the recurrence and relapse of cryocautery-induced gastric ulcer in rats: sequential observation with an endoscope and histological evaluation]. ( Arai, H; Doi, Y; Hashiba, K; Marubuchi, S; Mizuo, M; Mori, Y; Syouji, M, 1998) |
| "Effect of lafutidine ((+/-)-2-(furfurylsulfinyl)-N-[4-[4-(piperidinomethyl)-2-pyr idyl] oxy-(Z)-2-butenyl] acetamide, FRG-8813), a novel antiulcer agent, on the healing and relapse in acetic acid-induced gastric ulcer in rats was investigated." | 3.70 | [Effect of lafutidine, a novel antiulcer agent, on healing and relapse of acetic acid-induced gastric ulcer in rats]. ( Aoyama, M; Arai, Y; Ohnishi, H; Onodera, S; Shibata, M; Tanaka, M; Yamaura, T, 1998) |
| "We retrospectively investigated the efficacy of high dose omeprazole compared to a combined therapy of famotidine, pirenzepine and antacid for acute upper gastrointestinal hemorrhage (AUGIH) also adjuvant to endoscopic injection therapy if indicated." | 3.69 | [High-dose omeprazole versus famotidine, pirenzepine and antacid in therapy of acute upper gastrointestinal hemorrhage in a retrospective comparison]. ( Busam, J; Garbe, WE, 1994) |
| "In this open trial, 25 patients with identified duodenal ulcers were given long-term therapy of a single evening dose of 20 mg famotidine." | 3.68 | [Prevention of the recurrence of duodenal ulcer with famotidine. Report of experiences with long-term therapy in an open clinical study]. ( Judmaier, G, 1992) |
| "48 patients in whom previous endoscopic signs of chronic gastritis had been abolished by treatment with either 1 g sucralfate three times daily or 40 mg famotidine at night were followed up for 3 months without further therapy." | 3.68 | Follow-up of endoscopic gastritis after healing with sucralfate or an H2-receptor antagonist. ( Ballarin, E; Fanti, L; Guslandi, M; Sorghi, M; Tittobello, A, 1992) |
| " Subjects underwent EMR with circumferential mucosal incision assisted by submucosal injection of sodium hyaluronate (EMRSH), followed by IV or oral (PO) administration of famotidine at a dosage of 40 mg/day for 2 days." | 2.71 | Comparison of hemostatic effects by route of H2 receptor antagonist administration following endoscopic mucosal resection in patients with neoplastic gastric lesions. ( Ajibe, H; Hanatsuka, K; Hirasawa, T; Kawata, H; Kita, H; Osawa, H; Satoh, K; Satoh, Y; Sugano, K; Sunada, F; Sunada, K; Yamamoto, H; Yoshizawa, M, 2005) |
| "for the prevention of duodenal ulcer recurrence." | 2.67 | A controlled study of 20 mg famotidine nocte vs. 150 mg ranitidine nocte for the prevention of duodenal ulcer relapse. ( Barbara, L; Bianchi Porro, G; Blasi, A; Bovero, E; Capurso, L; Cheli, R; Corinaldesi, R; Koch, M; Lazzaroni, M; Mangiameli, A, 1991) |
| "H2-blockers reduce the annual recurrence from nearly 70% to about 25%." | 2.66 | H2-receptor antagonists and duodenal ulcer recurrence: analysis of efficacy and commentary on safety, costs, and patient selection. ( Freston, JW, 1987) |
| " While very safe, clinicians need to know correct dosing guidelines, drug interactions, and side effect profiles." | 2.38 | The clinical use of histamine-2 receptor antagonists. ( Michocki, RJ; Richardson, JP, 1992) |
| "It is not clear in which cases GERD should be suspected or how effective the GERD therapy is in treating the asthma." | 1.35 | [Gastroesophageal reflux disease in preschool children with asthma]. ( Doi, S; Kameda, M; Nishikido, T; Takamatu, I; Yoshida, Y, 2008) |
| "None of these 15 patients had a recurrence 3 months later." | 1.28 | The histological maturity of regenerating mucosa of healed duodenal ulcer and ulcer recurrence after treatment with H2-antagonist. ( Liao, CH; Pan, S, 1990) |
| "Operative management also reduces recurrence rates, which, however, are commoner in patients coming to surgery nowadays." | 1.28 | High doses of ranitidine in maintenance therapy of duodenal ulcer patients. ( Lee, FI, 1990) |
| "Famotidine is a potent H2 receptor antagonist containing a thiazole ring structure, thus differing chemically from cimetidine and ranitidine." | 1.27 | Famotidine. The ACG Committee on FDA-Related Matters with primary authorship by G. Friedman. American College of Gastroenterology. ( , 1987) |
| "Famotidine was effective in greater than or equal to 88% of patients with peptic ulcers and in 78." | 1.27 | Clinical benefits of intravenously administered famotidine in the treatment of upper gastrointestinal hemorrhage caused by peptic ulcer and stress ulcer disease. ( Aoki, T, 1987) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 8 (17.78) | 18.7374 |
| 1990's | 25 (55.56) | 18.2507 |
| 2000's | 8 (17.78) | 29.6817 |
| 2010's | 3 (6.67) | 24.3611 |
| 2020's | 1 (2.22) | 2.80 |
| Authors | Studies |
|---|---|
| Wong, GLH | 1 |
| Lau, LHS | 1 |
| Ching, JYL | 1 |
| Tse, YK | 2 |
| Ling, RHY | 1 |
| Wong, VWS | 1 |
| Chiu, PWY | 1 |
| Lau, JYW | 1 |
| Chan, FKL | 1 |
| Huertas-Ceballos, AA | 1 |
| Logan, S | 2 |
| Bennett, C | 2 |
| Macarthur, C | 2 |
| Martin, AE | 1 |
| Chan, FK | 1 |
| Kyaw, M | 1 |
| Tanigawa, T | 1 |
| Higuchi, K | 1 |
| Fujimoto, K | 1 |
| Cheong, PK | 1 |
| Lee, V | 1 |
| Kinoshita, Y | 1 |
| Naito, Y | 1 |
| Watanabe, T | 1 |
| Ching, JY | 1 |
| Lam, K | 1 |
| Lo, A | 1 |
| Chan, H | 1 |
| Lui, R | 1 |
| Tang, RS | 1 |
| Sakata, Y | 1 |
| Takeuchi, T | 1 |
| Handa, O | 1 |
| Nebiki, H | 1 |
| Wu, JC | 1 |
| Abe, T | 1 |
| Mishiro, T | 1 |
| Ng, SC | 1 |
| Arakawa, T | 1 |
| Hsu, PI | 1 |
| Wu, DC | 1 |
| Tsay, FW | 1 |
| Cheng, JS | 1 |
| Liu, CP | 1 |
| Lai, KH | 1 |
| Chen, WC | 1 |
| Wang, HM | 1 |
| Tsai, TJ | 1 |
| Tsai, KW | 1 |
| Kao, SS | 1 |
| Yoshida, Y | 1 |
| Kameda, M | 1 |
| Nishikido, T | 1 |
| Takamatu, I | 1 |
| Doi, S | 1 |
| Weydert, JA | 1 |
| Ball, TM | 1 |
| Davis, MF | 1 |
| Satoh, K | 1 |
| Yamamoto, H | 1 |
| Kawata, H | 1 |
| Osawa, H | 1 |
| Hanatsuka, K | 1 |
| Kita, H | 1 |
| Sunada, K | 1 |
| Hirasawa, T | 1 |
| Yoshizawa, M | 1 |
| Ajibe, H | 1 |
| Satoh, Y | 1 |
| Sunada, F | 1 |
| Sugano, K | 1 |
| Mine, S | 1 |
| Iida, T | 1 |
| Tabata, T | 1 |
| Kishikawa, H | 1 |
| Tanaka, Y | 1 |
| Huertas-Ceballos, A | 1 |
| Masci, E | 1 |
| Colombo, E | 1 |
| Testoni, PA | 1 |
| Fanti, L | 2 |
| Guslandi, M | 2 |
| Tittobello, A | 2 |
| Sobhani, I | 1 |
| Chastang, C | 1 |
| De Korwin, JD | 1 |
| Lamouliatte, H | 1 |
| Mégraud, F | 1 |
| Guerre, J | 1 |
| Elouaer-Blanc, L | 1 |
| Dominguez, HL | 1 |
| Freston, JW | 2 |
| Arizón Deza, P | 1 |
| García Tenorio, A | 1 |
| Gonzalo Til, A | 1 |
| Manero Ruiz, I | 1 |
| Mur Lalueza, MJ | 1 |
| Pascual Parrilla, MS | 1 |
| Lin, JT | 1 |
| Wang, JT | 1 |
| Wu, MS | 1 |
| Lee, WY | 1 |
| Yang, JC | 1 |
| Wang, TH | 1 |
| Busam, J | 1 |
| Garbe, WE | 1 |
| Misra, SC | 1 |
| Dasarathy, S | 1 |
| Sharma, MP | 1 |
| Gabryelewicz, A | 1 |
| Kosidło, S | 1 |
| Marlicz, K | 1 |
| Jaroszewicz-Heigelmann, H | 1 |
| Sakaki, N | 1 |
| Takemoto, T | 1 |
| Mann, SG | 2 |
| Cottrell, J | 2 |
| Murakami, A | 1 |
| Stauffer, L | 1 |
| Rao, AN | 1 |
| Haga, Y | 1 |
| Nakatsura, T | 1 |
| Shibata, Y | 1 |
| Sameshima, H | 1 |
| Nakamura, Y | 1 |
| Tanimura, M | 1 |
| Ogawa, M | 1 |
| Onodera, S | 1 |
| Tanaka, M | 1 |
| Aoyama, M | 1 |
| Arai, Y | 1 |
| Shibata, M | 1 |
| Yamaura, T | 1 |
| Ohnishi, H | 1 |
| Mori, Y | 1 |
| Doi, Y | 1 |
| Hashiba, K | 1 |
| Syouji, M | 1 |
| Mizuo, M | 1 |
| Marubuchi, S | 1 |
| Arai, H | 1 |
| Rollan, A | 1 |
| Giancaspero, R | 1 |
| Fuster, F | 1 |
| Acevedo, C | 1 |
| Figueroa, C | 1 |
| Hola, K | 1 |
| Schulz, M | 1 |
| Duarte, I | 1 |
| Shlevkov, BA | 1 |
| Abramova, LA | 1 |
| Toguzova, DA | 1 |
| Nikiforov, PA | 1 |
| Bazarova, MA | 1 |
| Nikitina, SA | 1 |
| Osin, VL | 1 |
| Shugurov, VA | 1 |
| Walt, RP | 1 |
| Freemantle, NP | 1 |
| Langman, MJ | 1 |
| Ballarin, E | 1 |
| Sorghi, M | 1 |
| Judmaier, G | 1 |
| Dragosics, B | 1 |
| Weiss, W | 1 |
| Okulski, G | 1 |
| Hotz, J | 1 |
| Kleinert, R | 1 |
| Grymbowski, T | 1 |
| Hennig, U | 1 |
| Schwarz, JA | 1 |
| Michocki, RJ | 1 |
| Richardson, JP | 1 |
| Berlin, RG | 1 |
| Root, JK | 1 |
| Cook, TJ | 1 |
| Bianchi Porro, G | 1 |
| Lazzaroni, M | 1 |
| Barbara, L | 2 |
| Corinaldesi, R | 1 |
| Blasi, A | 2 |
| Mangiameli, A | 1 |
| Capurso, L | 1 |
| Koch, M | 1 |
| Cheli, R | 2 |
| Bovero, E | 1 |
| Bianchi-Porro, G | 2 |
| Pace, F | 1 |
| Sangaletti, O | 1 |
| Peracchia, A | 1 |
| Bonavina, L | 1 |
| Vigneri, S | 1 |
| Termini, R | 1 |
| Pan, S | 1 |
| Liao, CH | 1 |
| Sikiric, P | 1 |
| Rotkvic, I | 1 |
| Mise, S | 1 |
| Petek, M | 1 |
| Rucman, R | 1 |
| Seiwerth, S | 1 |
| Zjacic-Rotkvic, V | 1 |
| Duvnjak, M | 1 |
| Jagic, V | 1 |
| Suchanek, E | 1 |
| Lee, FI | 1 |
| Reynolds, JC | 1 |
| Materia, A | 1 |
| Genco, A | 1 |
| Silecchia, G | 1 |
| Basso, N | 1 |
| Baglioni, A | 1 |
| Canelli, B | 1 |
| Dal Monte, R | 1 |
| Dammann, HG | 1 |
| Francavilla, A | 1 |
| Hentschel, E | 1 |
| Aoki, T | 1 |
| Tomasko, MA | 1 |
| Luskin, AT | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Prevention of Recurrent Idiopathic Gastroduodenal Ulcer Bleeding: a Double-blind Randomized Trial[NCT01180179] | Phase 4 | 228 participants (Actual) | Interventional | 2010-06-30 | Completed | ||
| Randomized Controlled Trial of Food Elimination Based on IgG Antibodies for Treatment of Functional Gastrointestinal Diseases (FGIDs) in Children[NCT02565355] | 60 participants (Actual) | Interventional | 2015-09-30 | Completed | |||
| Histamine-2 Receptor Antagonist Versus Proton-Pump Inhibitor for the Prevention of Recurrent Upper Gastrointestinal Bleeding (UGI) in High-risk Users of Low-dose Aspirin (ASA)[NCT01408186] | Phase 3 | 264 participants (Actual) | Interventional | 2011-01-31 | Completed | ||
| Diagnosis of Acid Reflux Disease Using Novel Imaging: A Prospective Study[NCT02081404] | 98 participants (Actual) | Interventional | 2009-03-01 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
4 reviews available for famotidine and Recrudescence
| Article | Year |
|---|---|
WITHDRAWN: Pharmacological interventions for recurrent abdominal pain (RAP) and irritable bowel syndrome (IBS) in childhood.
Topics: Abdominal Pain; Adolescent; Analgesics, Non-Narcotic; Child; Child, Preschool; Famotidine; Humans; I | 2014 |
Systematic review of treatments for recurrent abdominal pain.
Topics: Abdominal Pain; Adolescent; Behavior Therapy; Biofeedback, Psychology; Child; Child, Preschool; Diet | 2003 |
Pharmacological interventions for recurrent abdominal pain (RAP) and irritable bowel syndrome (IBS) in childhood.
Topics: Abdominal Pain; Adolescent; Analgesics, Non-Narcotic; Child; Child, Preschool; Famotidine; Humans; I | 2008 |
The clinical use of histamine-2 receptor antagonists.
Topics: Cimetidine; Drug Evaluation; Famotidine; Gastroesophageal Reflux; Humans; Nizatidine; Peptic Ulcer; | 1992 |
22 trials available for famotidine and Recrudescence
| Article | Year |
|---|---|
Prevention of recurrent idiopathic gastroduodenal ulcer bleeding: a double-blind, randomised trial.
Topics: Aged; Aged, 80 and over; Double-Blind Method; Duodenal Ulcer; Famotidine; Female; Histamine H2 Antag | 2020 |
Similar Efficacy of Proton-Pump Inhibitors vs H2-Receptor Antagonists in Reducing Risk of Upper Gastrointestinal Bleeding or Ulcers in High-Risk Users of Low-Dose Aspirin.
Topics: Aged; Aged, 80 and over; Aspirin; Double-Blind Method; Famotidine; Female; Hemoglobins; Histamine H2 | 2017 |
Histamine-2 Receptor Antagonist Cannot Prevent Recurrent Peptic Ulcers in Patients With Atherosclerotic Diseases Who Receive Platelet ADP Receptor Antagonist Monotherapy: A Randomized-Controlled, Double-Blind, and Double-Dummy Trial.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Atherosclerosis; Clopidogrel; Double-Blind Method; F | 2017 |
Comparison of hemostatic effects by route of H2 receptor antagonist administration following endoscopic mucosal resection in patients with neoplastic gastric lesions.
Topics: Adenocarcinoma; Adjuvants, Immunologic; Administration, Oral; Aged; Endoscopy, Gastrointestinal; Fam | 2005 |
Management of symptoms in step-down therapy of gastroesophageal reflux disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Deglutition Disorders; Endosonography; Enzyme Inhibit | 2005 |
Colloid bismuth versus famotidine in the treatment and prevention of duodenal ulcer relapse: results of a double-blind, double dummy randomized study.
Topics: Antacids; Anti-Ulcer Agents; Bismuth; Colloids; Double-Blind Method; Duodenal Ulcer; Endoscopy, Gast | 1995 |
Antibiotic versus maintenance therapy in the prevention of duodenal ulcer recurrence. Results of a multicentric double-blind randomized trial.
Topics: Adult; Amoxicillin; Double-Blind Method; Drug Therapy, Combination; Duodenal Ulcer; Famotidine; Fema | 1995 |
Prospective, randomized study of H2-blocker and triple therapy for duodenal ulcer treatment and the eradication of Helicobacter pylori.
Topics: Adult; Amoxicillin; Bismuth; Drug Therapy, Combination; Duodenal Ulcer; Famotidine; Female; Helicoba | 1994 |
Omeprazole versus famotidine in the healing and relapse of duodenal ulcer.
Topics: Absenteeism; Adult; Analgesics; Antacids; Double-Blind Method; Duodenal Ulcer; Famotidine; Female; H | 1993 |
[Clinical evaluation of one-year controlled studies of duodenal ulcer recurrence rate in patients treated with the preparation Ulfamid].
Topics: Adult; Duodenal Ulcer; Famotidine; Female; Follow-Up Studies; Humans; Male; Recurrence | 1993 |
Prevention of heartburn relapse by low-dose famotidine: a test meal model for duration of symptom control.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Alginates; Double-Blind Method; Famotidine; Female; Gluc | 1997 |
Continuous intravenous famotidine for haemorrhage from peptic ulcer.
Topics: Aged; Aged, 80 and over; Famotidine; Female; Gastric Mucosa; Hemoglobins; Humans; Infusions, Intrave | 1992 |
[Therapy of peptic ulcers with famotidine. Report of experiences with an open clinical study].
Topics: Adult; Aged; Aged, 80 and over; Chronic Disease; Dose-Response Relationship, Drug; Drug Administrati | 1992 |
Lansoprazole versus famotidine: efficacy and tolerance in the acute management of duodenal ulceration.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Double-Blind Method; Duoden | 1992 |
Nocturnal therapy with famotidine for 1 year is effective in preventing relapse of gastric ulcer.
Topics: Adult; Double-Blind Method; Famotidine; Female; Humans; Male; Middle Aged; Recurrence; Stomach Ulcer | 1991 |
A controlled study of 20 mg famotidine nocte vs. 150 mg ranitidine nocte for the prevention of duodenal ulcer relapse.
Topics: Adult; Aged; Double-Blind Method; Duodenal Ulcer; Famotidine; Female; Humans; Male; Middle Aged; Ran | 1991 |
High-dose famotidine in the maintenance treatment of refractory esophagitis: results of a "medium-term" open study.
Topics: Adult; Double-Blind Method; Esophagitis; Esophagoscopy; Famotidine; Female; Humans; Male; Middle Age | 1991 |
Dopamine agonists prevent duodenal ulcer relapse. A comparative study with famotidine and cimetidine.
Topics: Adult; Aged; Amantadine; Bromocriptine; Cimetidine; Duodenal Ulcer; Famotidine; Female; Humans; Male | 1991 |
Famotidine therapy for active duodenal ulcers. A multivariate analysis of factors affecting early healing.
Topics: Adult; Aged; Aged, 80 and over; Alcohol Drinking; Anti-Inflammatory Agents, Non-Steroidal; Duodenal | 1989 |
[Famotidine versus placebo in prevention of the recurrence of duodenal ulcer disease. A multicenter study in Germany, Austria and Italy].
Topics: Adult; Austria; Clinical Trials as Topic; Double-Blind Method; Drug Administration Schedule; Duodena | 1985 |
Famotidine (Pepcid).
Topics: Clinical Trials as Topic; Duodenal Ulcer; Famotidine; Gastric Acid; Histamine H2 Antagonists; Humans | 1987 |
H2-receptor antagonists and duodenal ulcer recurrence: analysis of efficacy and commentary on safety, costs, and patient selection.
Topics: Cimetidine; Clinical Trials as Topic; Costs and Cost Analysis; Duodenal Ulcer; Famotidine; Histamine | 1987 |
19 other studies available for famotidine and Recrudescence
| Article | Year |
|---|---|
[Gastroesophageal reflux disease in preschool children with asthma].
Topics: Androstadienes; Asthma; Child, Preschool; Diagnosis, Differential; Esophageal pH Monitoring; Famotid | 2008 |
Peptic ulcer disease in adolescence: changing concepts in the age of Helicobacter pylori.
Topics: Adolescent; Adult; Anti-Ulcer Agents; Duodenal Ulcer; Famotidine; Helicobacter Infections; Helicobac | 1994 |
[Maintenance therapy with antiulcer drugs: review of 71 cases].
Topics: Aluminum Hydroxide; Antacids; Anti-Ulcer Agents; Carbonates; Cross-Over Studies; Duodenal Ulcer; Fam | 1995 |
[High-dose omeprazole versus famotidine, pirenzepine and antacid in therapy of acute upper gastrointestinal hemorrhage in a retrospective comparison].
Topics: Aged; Aged, 80 and over; Aluminum Hydroxide; Antacids; Dose-Response Relationship, Drug; Drug Admini | 1994 |
The relationship between endoscopic findings of gastric ulcer scar and ulcer relapse.
Topics: Adult; Aged; Aged, 80 and over; Famotidine; Female; Gastric Mucosa; Gastroscopy; Humans; Male; Middl | 1993 |
Human gastric carcinoid detected during long-term antiulcer therapy of H2 receptor antagonist and proton pump inhibitor.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Carcinoid Tumor; Famotidine; Hist | 1998 |
[Effect of lafutidine, a novel antiulcer agent, on healing and relapse of acetic acid-induced gastric ulcer in rats].
Topics: Acetamides; Acetic Acid; Animals; Anti-Ulcer Agents; Cimetidine; Dose-Response Relationship, Drug; F | 1998 |
[Influence of T-593 on the recurrence and relapse of cryocautery-induced gastric ulcer in rats: sequential observation with an endoscope and histological evaluation].
Topics: Animals; Anti-Ulcer Agents; Cautery; Cryosurgery; Endoscopy; Famotidine; Guanidines; Histamine H2 An | 1998 |
The long-term reinfection rate and the course of duodenal ulcer disease after eradication of Helicobacter pylori in a developing country.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Ulcer Agents; Chile; Developing Countries; Drug Therapy, | 2000 |
[Experience in clinical use of quamatel in upper gastrointestinal hemorrhage].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Algorithms; Duodenal Ulcer; Famotidine; Female; Gastroin | 2001 |
[H2 blockers in the treatment of bleeding gastroduodenal ulcers].
Topics: Adolescent; Adult; Aged; Anti-Ulcer Agents; Duodenal Ulcer; Duodenoscopy; Famotidine; Female; Gastro | 2001 |
Follow-up of endoscopic gastritis after healing with sucralfate or an H2-receptor antagonist.
Topics: Famotidine; Female; Follow-Up Studies; Gastritis; Gastroscopy; Humans; Male; Recurrence; Sucralfate; | 1992 |
[Prevention of the recurrence of duodenal ulcer with famotidine. Report of experiences with long-term therapy in an open clinical study].
Topics: Adult; Dose-Response Relationship, Drug; Drug Administration Schedule; Duodenal Ulcer; Duodenoscopy; | 1992 |
The histological maturity of regenerating mucosa of healed duodenal ulcer and ulcer recurrence after treatment with H2-antagonist.
Topics: Adolescent; Adult; Aged; Cimetidine; Duodenal Ulcer; Duodenoscopy; Famotidine; Female; Histamine H2 | 1990 |
High doses of ranitidine in maintenance therapy of duodenal ulcer patients.
Topics: Cimetidine; Duodenal Ulcer; Famotidine; Humans; Ranitidine; Recurrence; Smoking | 1990 |
Failure of single night-time dose of H2-receptor antagonists in the treatment of duodenal ulcer patients with bulbar stenosis.
Topics: Adult; Aged; Drug Administration Schedule; Duodenal Obstruction; Duodenal Ulcer; Famotidine; Female; | 1989 |
Famotidine. The ACG Committee on FDA-Related Matters with primary authorship by G. Friedman. American College of Gastroenterology.
Topics: Duodenal Ulcer; Famotidine; Gastric Acid; Histamine H2 Antagonists; Humans; Recurrence; Stomach Ulce | 1987 |
Clinical benefits of intravenously administered famotidine in the treatment of upper gastrointestinal hemorrhage caused by peptic ulcer and stress ulcer disease.
Topics: Endoscopy; Famotidine; Histamine H2 Antagonists; Humans; Infusions, Intravenous; Peptic Ulcer Hemorr | 1987 |
Recurrent parotitis with H2 receptor antagonists in a patient with Sjogren's syndrome.
Topics: Cimetidine; Famotidine; Female; Histamine H2 Antagonists; Humans; Middle Aged; Parotitis; Ranitidine | 1988 |